狭心症治療薬の市場：タイプ、薬剤、投与経路、流通チャネル、エンドユーザー別-2025-2030年の世界予測

狭心症治療薬市場は、2023年に11億4,000万米ドルと評価され、2024年には12億米ドルに達すると予測され、CAGR 5.39％で成長し、2030年には16億5,000万米ドルに達すると予測されています。

狭心症治療薬の対象範囲には、心臓への血流不足に起因する胸痛に伴う症状の治療と管理が含まれます。このカテゴリーには、硝酸薬、β遮断薬、カルシウム拮抗薬、抗血小板薬などの薬剤が含まれ、狭心症症状の緩和や心臓発作の予防に極めて重要です。これらの薬剤の必要性は、心血管系疾患の世界の流行と高齢者人口の増加によって強調されており、慢性的なケア管理において不可欠なものとなっています。その用途は症状の緩和だけにとどまらず、患者のQOLの向上や主要な心血管イベントの発生率の低下にも不可欠です。主な最終用途市場には、病院、診療所、小売薬局が含まれ、医療インフラと意識の高まりにより新興国市場での利用が拡大しています。

市場開拓と個別化医療の進展は、ヘルスケア支出の増加とともに、市場成長の主な要因となっています。新たなビジネスチャンスは、進行中の研究と医薬品の技術革新に後押しされた、冠動脈疾患に関与する特定の経路を標的とする新規治療薬の開発にあります。予防医療と生活習慣の改善への注目の高まりは、市場浸透のさらなる機会をもたらします。しかし、厳しい規制環境、新薬開発の高コスト、患者のコンプライアンス違反につながる副作用の可能性などにより、成長は抑制されています。

主な課題としては、特許切れによるジェネリック医薬品との競合や、低所得者層市場における有効性と価格とのバランスの必要性などが挙げられます。遺伝子治療、配合剤の開発、人工知能を活用した患者の反応予測や製剤の最適化などの分野でイノベーションが進展する可能性があります。複雑な患者のニーズを理解し、研究開発に投資することで、飛躍的な進歩を遂げることができます。戦略的パートナーシップや地方市場への浸透を通じた市場拡大への積極的なアプローチは、アクセシビリティを高めることができます。狭心症治療薬市場はダイナミックであり、臨床イノベーションによって大きな成長の可能性を秘めているが、こうした展望を十分に実現するためには、規制面や経済面での課題を乗り越えていく必要があります。

市場力学：急速に進化する狭心症治療薬市場の主要市場インサイトを公開

狭心症治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 心臓関連疾患の増加に伴う生活習慣病の負担増
  • 新規ドラッグデリバリーシステムの増加
  • 心血管疾患の予防と管理強化における政府の支援
• 市場抑制要因
  • 特定の薬剤クラスに関連する副作用に関する懸念
• 市場機会
  • 個別化された心血管医療に向けた技術の進歩
  • 医薬品承認数と臨床研究の急増
• 市場の課題
  • 熟練した経験豊富な専門家の不足

ポーターの5つの力：狭心症治療薬市場をナビゲートする戦略ツール

ポーターの5つの力」フレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：狭心症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、狭心症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析狭心症治療薬市場における競合情勢の把握

狭心症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス狭心症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、狭心症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨狭心症治療薬市場における成功への道筋を描く

狭心症治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 生活習慣病の負担増加と心臓関連疾患の増加
    • 新しいドラッグデリバリーシステムの増強
    • 心血管疾患の予防と管理の強化に対する政府の支援
  • 抑制要因
    • 特定の薬物クラスに関連する副作用に関する懸念
  • 機会
    • 個別化心臓血管医療に向けた技術の進歩
    • 医薬品の承認と臨床調査の増加
  • 課題
    • 熟練した経験豊富な専門家の不足
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 狭心症治療薬の市場：タイプ別

• プリンツメタル狭心症
• 安定狭心症
• 不安定狭心症

第7章 狭心症治療薬の市場薬物別

• 抗虚血剤
• 降圧剤
• 抗血小板薬
• ベータ遮断薬
• カルシウムチャネル遮断薬
• 硝酸塩
• スタチン

第8章 狭心症治療薬の市場：投与経路別

• オーラル
• 非経口
• 経皮

第9章 狭心症治療薬の市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第10章 狭心症治療薬の市場：エンドユーザー別

• ホームケア
• 病院
• 専門クリニック

第11章 南北アメリカの狭心症治療薬の市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の狭心症治療薬の市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの狭心症治療薬の市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Alembic Pharmaceuticals Limited
• Alkem Laboratories Ltd.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Bayer AG
• Centurion Remedies Private Limited
• Dr. Reddy's Laboratories
• Eli Lilly and Company
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Intas Pharmaceuticals Ltd.
• Ipca Laboratories Ltd.
• Lupin Ltd.
• Macleods Pharmaceuticals Pvt Ltd.
• Mankind Pharma
• Merck & Co. Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Sanofi-Aventis Groupe S.A.
• Sumitomo Corporation
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.

LIST OF FIGURES

• FIGURE 1. ANGINA PECTORIS DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. ANGINA PECTORIS DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. ANGINA PECTORIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. ANGINA PECTORIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANGINA PECTORIS DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANGINA PECTORIS DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY PRINZMETAL ANGINA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ANTI-ISCHEMIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ANTIHYPERTENSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY BETA-ADRENERGIC BLOCKING AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY NITRATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 47. CANADA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CANADA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 49. CANADA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. CANADA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. CANADA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 74. CHINA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. CHINA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 76. CHINA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. CHINA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. CHINA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 79. INDIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. INDIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 81. INDIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. INDIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. INDIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 165. ITALY ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. ITALY ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 167. ITALY ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 168. ITALY ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. ITALY ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 185. POLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. POLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 187. POLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. POLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. POLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 190. QATAR ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 191. QATAR ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 192. QATAR ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 193. QATAR ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. QATAR ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 240. ANGINA PECTORIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 241. ANGINA PECTORIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Angina Pectoris Drugs Market was valued at USD 1.14 billion in 2023, expected to reach USD 1.20 billion in 2024, and is projected to grow at a CAGR of 5.39%, to USD 1.65 billion by 2030.

The scope of angina pectoris drugs encompasses the treatment and management of symptoms associated with chest pain resulting from insufficient blood flow to the heart. This category includes medications like nitrates, beta-blockers, calcium channel blockers, and antiplatelet agents, which are crucial for alleviating angina symptoms and preventing heart attacks. The necessity of these drugs is underscored by the global prevalence of cardiovascular diseases and the rising geriatric population, making them indispensable in chronic care management. Their applications extend beyond symptom relief; they're integral in improving patient quality of life and reducing the incidence of major cardiovascular events. Primary end-use markets include hospitals, clinics, and retail pharmacies, with expanding reach in developing regions due to increasing health infrastructure and awareness.

Market growth is predominantly influenced by advancements in drug development and personalized medicine, alongside increasing healthcare expenditures. Emerging opportunities lie in the development of novel therapeutics targeting specific pathways involved in coronary artery disease, driven by ongoing research and technological innovations in pharmaceuticals. An increasing focus on preventive care and lifestyle modifications presents further opportunities for market penetration. However, growth is tempered by stringent regulatory environments, high costs of novel drug development, and potential side effects leading to patient non-compliance.

Key challenges include the competition from generics due to patent expirations and the need to balance efficacy with affordability in low-income markets. Innovation can flourish in areas such as gene therapy, development of combination drugs, and leveraging artificial intelligence to better predict patient responses and optimize drug formulations. Understanding complex patient needs and investing in R&D can lead to breakthroughs. A proactive approach to market expansion through strategic partnerships and rural market penetration can enhance accessibility. The angina pectoris drugs market is dynamic, with significant potential for growth driven by clinical innovation, yet it requires navigating through regulatory and economic challenges to fully realize these prospects.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Angina Pectoris Drugs Market

The Angina Pectoris Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing burden of lifestyle diseases couple with rise in cases of heart related disorders
  • Augmentation of novel drug delivery systems
  • Government suppport in strengthening the prevention and control of cardiovascular disease
• Market Restraints
  • Concerns regarding side effects associated with certain drug classes
• Market Opportunities
  • Technological advancements towards personalized cardiovascular medicine
  • Proliferation in the number of drug approvals and clinical research
• Market Challenges
  • Dearth of skilled and experienced professionals

Porter's Five Forces: A Strategic Tool for Navigating the Angina Pectoris Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Angina Pectoris Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Angina Pectoris Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Angina Pectoris Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Angina Pectoris Drugs Market

A detailed market share analysis in the Angina Pectoris Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Angina Pectoris Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Angina Pectoris Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Angina Pectoris Drugs Market

A strategic analysis of the Angina Pectoris Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Angina Pectoris Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Centurion Remedies Private Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Intas Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Ltd., Macleods Pharmaceuticals Pvt Ltd., Mankind Pharma, Merck & Co. Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi-Aventis Groupe S.A., Sumitomo Corporation, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Angina Pectoris Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Prinzmetal Angina, Stable Angina, and Unstable Angina.
• Based on Drugs, market is studied across Anti-Ischemic Agents, Antihypertensive Agents, Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Nitrates, and Statins.
• Based on Route of Administration, market is studied across Oral, Parenteral, and Transdermal.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on End-Users, market is studied across Homecare, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing burden of lifestyle diseases couple with rise in cases of heart related disorders
    • 5.1.1.2. Augmentation of novel drug delivery systems
    • 5.1.1.3. Government suppport in strengthening the prevention and control of cardiovascular disease
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns regarding side effects associated with certain drug classes
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements towards personalized cardiovascular medicine
    • 5.1.3.2. Proliferation in the number of drug approvals and clinical research
  • 5.1.4. Challenges
    • 5.1.4.1. Dearth of skilled and experienced professionals
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Angina Pectoris Drugs Market, by Type

• 6.1. Introduction
• 6.2. Prinzmetal Angina
• 6.3. Stable Angina
• 6.4. Unstable Angina

7. Angina Pectoris Drugs Market, by Drugs

• 7.1. Introduction
• 7.2. Anti-Ischemic Agents
• 7.3. Antihypertensive Agents
• 7.4. Antiplatelet Agents
• 7.5. Beta-Adrenergic Blocking Agents
• 7.6. Calcium Channel Blockers
• 7.7. Nitrates
• 7.8. Statins

8. Angina Pectoris Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral
• 8.4. Transdermal

9. Angina Pectoris Drugs Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacy
• 9.3. Online Pharmacy
• 9.4. Retail Pharmacy

10. Angina Pectoris Drugs Market, by End-Users

• 10.1. Introduction
• 10.2. Homecare
• 10.3. Hospitals
• 10.4. Specialty Clinics

11. Americas Angina Pectoris Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Angina Pectoris Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Angina Pectoris Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alembic Pharmaceuticals Limited
• 2. Alkem Laboratories Ltd.
• 3. Astellas Pharma Inc.
• 4. AstraZeneca PLC
• 5. Bausch Health Companies Inc.
• 6. Bayer AG
• 7. Centurion Remedies Private Limited
• 8. Dr. Reddy's Laboratories
• 9. Eli Lilly and Company
• 10. Gilead Sciences, Inc.
• 11. GlaxoSmithKline PLC
• 12. Intas Pharmaceuticals Ltd.
• 13. Ipca Laboratories Ltd.
• 14. Lupin Ltd.
• 15. Macleods Pharmaceuticals Pvt Ltd.
• 16. Mankind Pharma
• 17. Merck & Co. Inc.
• 18. Novartis AG
• 19. Otsuka Pharmaceutical Co., Ltd.
• 20. Pfizer Inc.
• 21. Sanofi-Aventis Groupe S.A.
• 22. Sumitomo Corporation
• 23. Sun Pharmaceutical Industries Ltd.
• 24. Teva Pharmaceutical Industries Ltd.
• 25. Torrent Pharmaceuticals Ltd.